Jackson Park Capital’s Gilead Sciences GILD Stock Holding History

Jackson Park Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.08M	Sell	29,000 -11,000	-28%	-$818K	3.87%	8
2016 Q3	$3.17M	Hold	40,000	–	–	4.11%	6
2016 Q2	$3.34M	Sell	40,000 -4,810	-11%	-$427K	4.57%	3
2016 Q1	$4.12M	Sell	44,810 -3,000	-6%	-$271K	5.31%	3
2015 Q4	$4.84M	Hold	47,810	–	–	4.99%	3
2015 Q3	$4.69M	Hold	47,810	–	–	4.07%	7
2015 Q2	$5.6M	Hold	47,810	–	–	4.55%	5
2015 Q1	$4.69M	Sell	47,810 -8,190	-15%	-$832K	4.02%	9
2014 Q4	$5.28M	Buy	+56,000	New	+$5.79M	4.21%	6

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jackson Park Capital's GILD Position: Q4 2016 in Review

Jackson Park Capital reduced its Gilead Sciences (GILD) stake by 28% in Q4 2016, selling an estimated $818K and leaving 29,000 shares worth $2.08M. The position accounts for 3.87% of the portfolio, ranked #8.

Jackson Park Capital first reported a position in GILD in Q4 2014 and has held it in 9 quarters since. The position peaked at $5.6M in Q2 2015. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Jackson Park Capital held 29,000 shares of Gilead Sciences worth $2.08M as of Q4 2016.
Jackson Park Capital sold 11,000 Gilead Sciences shares in Q4 2016, an estimated $818K.
Gilead Sciences made up 3.87% of Jackson Park Capital's portfolio in Q4 2016, its #8 holding.
Jackson Park Capital first reported a position in Gilead Sciences in Q4 2014 and has held it in 9 quarters since.
Jackson Park Capital's Gilead Sciences position peaked at $5.6M in Q2 2015.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Jackson Park Capital's 13F filing for Q4 2016, filed 1 Feb 2017.